All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficient treatment option for patients with hematological malignancies. However, graft-versus-host disease (GvHD) remains a serious complication of allo‐HSCT which significantly affect transplant-related morbidity and mortality. Transplant outcomes can be improved by matching human leukocyte antigens, but other factors are needed to reduce the risk of GvHD.
Wei Wang from Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA, and colleagues aimed to identify genetic associations outside the major histocompatibility complex. Therefore, they conducted a genome-wide study on clinical outcomes including 205 acute myeloid leukemia (AML) patients (n = 102 acute GvHD; n = 103 non-GvHD), and their fully HLA-A–, HLA-B–, HLA-C–, HLA-DRB1–, and HLA-DQB1–matched (10/10) unrelated donors. Data was collected from the Center for International Blood and Bone Marrow Transplant Research (CIBMTR) database. Results were published in Blood Advances on October 9.
This study indicates that sex-linked variation exposed multiple MiHAs encoded on the Y chromosome contribute to the development of acute GvHD, particularly in female > male allo-HSCT patients. The authors added that “methods and results described here have an immediate impact for allo-HSCT, warranting further development and larger genomic studies where MiHAs are clinically relevant, including cancer immunotherapy, solid organ transplant, and pregnancy.”
Subscribe to get the best content related to GvHD delivered to your inbox